Acepodia, a clinical─stage biotechnology company developing first─in─class cell therapies with its unique antibody─cell conjugation (ACC) and...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Maroc - PHARMABIZ.COM - A la Une - 29/Aug 00:00
Ocugen completes dosing in subjects with Stargardt disease in high dose cohort of phase 1/2 GARDian trial of OCU410ST, a modifier gene therapy
Ocugen, Inc., a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, announced that dosing is complete in the third cohort of its
Articles similaires
Acepodia inks clinical collaboration with Pfizer to accelerate development of ACC─based cell therapies in autoimmune diseases
pharmabiz.com - 05/Sep 00:00
Acepodia, a clinical─stage biotechnology company developing first─in─class cell therapies with its unique antibody─cell conjugation (ACC) and...
Stealth BioTherapeutics to receive FARA grant to develop investigational mitochondrial therapeutic SBT─589 for Friedreich's ataxia
pharmabiz.com - 13/Sep 16:48
Stealth BioTherapeutics Inc., a clinical─stage biotechnology company focused on the discovery, development and commercialization of novel therapies...
Stealth BioTherapeutics to receive FARA grant to develop investigational mitochondrial therapeutic SBT─589 for Friedreich's ataxia
pharmabiz.com - 13/Sep 16:48
Stealth BioTherapeutics Inc., a clinical─stage biotechnology company focused on the discovery, development and commercialization of novel therapies...
Gene Therapies For Cardiomyopathies Market Growth Anticipated by 2032 | Companies includes Lexeo Therapeutics, expected to boost the market
mountaintoday.in - 12/Sep 07:49
Gene Therapies For Cardiomyopathies Market Gene Therapies For Cardiomyopathies Market Growth is expected due to increased interest from companies in...
Gene Therapies For Cardiomyopathies Market Growth Anticipated by 2032 | Companies includes Lexeo Therapeutics, expected to boost the market
mountaintoday.in - 12/Sep 07:49
Gene Therapies For Cardiomyopathies Market Gene Therapies For Cardiomyopathies Market Growth is expected due to increased interest from companies in...
Novartis to License VYGR's Capsid for Gene Therapy in Neurology
zacks.com - 06/Sep 13:22
NVS has decided to license a novel capsid generated from Voyager's TRACER platform for use in a gene therapy program against an undisclosed rare...
TC BioPharm to begin Proof of Concept preclinical studies for its lead therapeutic TCB 008 to treat monkey pox
pharmabiz.com - 09/Sep 00:00
TC BioPharm (Holdings) PLC (TC BioPharm), a clinical stage biotechnology company developing platform allogeneic gamma─delta T cell therapies for...
Les derniers communiqués
-
Aucun élément